BRPI0510950A - membro de ligação especìfico, composição farmacêutica, método para o tratamento de um tumor em um paciente, uso de um membro de ligação, produtos, ácido nucleico, e, carboidrato de sialiltetraosila - Google Patents

membro de ligação especìfico, composição farmacêutica, método para o tratamento de um tumor em um paciente, uso de um membro de ligação, produtos, ácido nucleico, e, carboidrato de sialiltetraosila

Info

Publication number
BRPI0510950A
BRPI0510950A BRPI0510950-7A BRPI0510950A BRPI0510950A BR PI0510950 A BRPI0510950 A BR PI0510950A BR PI0510950 A BRPI0510950 A BR PI0510950A BR PI0510950 A BRPI0510950 A BR PI0510950A
Authority
BR
Brazil
Prior art keywords
binding member
carbohydrate
tumor
patient
products
Prior art date
Application number
BRPI0510950-7A
Other languages
English (en)
Inventor
Linda Gillian Durrant
Tina Parsons
Original Assignee
Scancell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32526936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0510950(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scancell Ltd filed Critical Scancell Ltd
Publication of BRPI0510950A publication Critical patent/BRPI0510950A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MEMBRO DE LIGAçãO ESPECìFICO, COMPOSIçãO FARMACêUTICA, MéTODO PARA O TRATAMENTO DE UM TUMOR EM UM PACIENTE, USO DE UM MEMBRO DE LIGAçãO, PRODUTOS, áCIDO NUCLéICO, E, CARBOIDRATO DE SIALILTETRAOSILA A presente invenção provê um membro de ligação específico isolado capaz de ligar um carboidrato de sialiltetraosila e diretamente induzir a morte celular sem a necessidade de células efetoras imunes. Este membro de ligação pode ser um anticorpo ou uma parte do mesmo. Também são providos o uso destes membros de ligação em medicina e ácidos nucleicos codificando estes membros de ligação.
BRPI0510950-7A 2004-05-12 2005-05-11 membro de ligação especìfico, composição farmacêutica, método para o tratamento de um tumor em um paciente, uso de um membro de ligação, produtos, ácido nucleico, e, carboidrato de sialiltetraosila BRPI0510950A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0410627.4A GB0410627D0 (en) 2004-05-12 2004-05-12 Specific binding members
PCT/GB2005/001805 WO2005108430A2 (en) 2004-05-12 2005-05-11 Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent

Publications (1)

Publication Number Publication Date
BRPI0510950A true BRPI0510950A (pt) 2007-11-20

Family

ID=32526936

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510950-7A BRPI0510950A (pt) 2004-05-12 2005-05-11 membro de ligação especìfico, composição farmacêutica, método para o tratamento de um tumor em um paciente, uso de um membro de ligação, produtos, ácido nucleico, e, carboidrato de sialiltetraosila

Country Status (16)

Country Link
US (2) US7915387B2 (pt)
EP (3) EP2392598A1 (pt)
JP (2) JP4944016B2 (pt)
KR (1) KR101213282B1 (pt)
CN (1) CN1961004B (pt)
AU (2) AU2005240837B2 (pt)
BR (1) BRPI0510950A (pt)
CA (1) CA2563516C (pt)
ES (1) ES2400571T3 (pt)
GB (1) GB0410627D0 (pt)
IL (1) IL178791A (pt)
MX (1) MXPA06012955A (pt)
NO (1) NO20065651L (pt)
NZ (3) NZ589214A (pt)
WO (1) WO2005108430A2 (pt)
ZA (1) ZA200609365B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
EP2433967A3 (en) * 2009-03-16 2013-05-01 Cephalon Australia Pty Ltd Humanised antibodies with anti-tumour activity
CA2778552A1 (en) * 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Treatment of cancer involving mutated kras or braf genes
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
US10544231B2 (en) * 2014-04-16 2020-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS5811808A (ja) 1981-07-16 1983-01-22 Niles Parts Co Ltd 方位検出表示回路
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4630115A (en) 1983-05-09 1986-12-16 The General Electric Company, P.L.C. Cathode ray tube display device
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2082160C (en) 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
PT699237E (pt) * 1994-03-17 2003-07-31 Merck Patent Gmbh Fvs de cadeia anti-egfr e anticorpos anti-egfr
JPH09173063A (ja) 1995-12-26 1997-07-08 Cosmo Sogo Kenkyusho:Kk 抗ヒトリポタンパク質（ａ）モノクローナル抗体可変領域のＤＮＡ塩基配列およびアミノ酸配列
WO1997034634A1 (en) * 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6350860B1 (en) 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
AU2002311919B8 (en) 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
CN1961004A (zh) 2007-05-09
CN1961004B (zh) 2012-11-07
GB0410627D0 (en) 2004-06-16
JP2008502324A (ja) 2008-01-31
JP2012105654A (ja) 2012-06-07
WO2005108430A3 (en) 2006-04-27
NZ550738A (en) 2011-03-31
AU2011200487A1 (en) 2011-02-24
US7915387B2 (en) 2011-03-29
EP2392598A1 (en) 2011-12-07
IL178791A0 (en) 2007-03-08
US20110212113A1 (en) 2011-09-01
EP2397500A1 (en) 2011-12-21
CA2563516C (en) 2013-10-01
IL178791A (en) 2012-07-31
CA2563516A1 (en) 2005-11-17
AU2005240837B2 (en) 2010-11-11
US20080118509A1 (en) 2008-05-22
JP4944016B2 (ja) 2012-05-30
KR20070085116A (ko) 2007-08-27
NZ589214A (en) 2012-02-24
US8343490B2 (en) 2013-01-01
ES2400571T3 (es) 2013-04-10
AU2011200487B2 (en) 2012-11-01
HK1101696A1 (en) 2007-10-26
NO20065651L (no) 2007-02-06
AU2005240837A1 (en) 2005-11-17
MXPA06012955A (es) 2007-04-25
KR101213282B1 (ko) 2012-12-17
EP1745077B1 (en) 2012-11-28
NZ593171A (en) 2012-08-31
ZA200609365B (en) 2008-05-28
WO2005108430A2 (en) 2005-11-17
EP1745077A2 (en) 2007-01-24

Similar Documents

Publication Publication Date Title
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
CY1112110T1 (el) Κυκλικο μοριο dna το οποιο διαθετει μια συμβατικη αφετηρια αντιγραφης, η διαδικασια παρασκευης του και η χρηση του στην γονιδιακη θεραπεια
WO2010129023A3 (en) Supercharged proteins for cell penetration
TR200400149T2 (tr) Tümörlerin teşhisi ve tedavisi için mikroorganizmalar ve hücreler
EA200870129A1 (ru) Человеческие антитела против il-23, композиции, способы и применение
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
DE60138641D1 (de) Herstellung von mikrokügelchen
MX2007007033A (es) Estreptococus del grupo b.
WO2002004514A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
BRPI0707488B8 (pt) método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável
WO2003029429A3 (en) Traversal of nucleic acid molecules through a fluid space and expression in repair cells
BRPI0510950A (pt) membro de ligação especìfico, composição farmacêutica, método para o tratamento de um tumor em um paciente, uso de um membro de ligação, produtos, ácido nucleico, e, carboidrato de sialiltetraosila
DE60132443D1 (de) In lebenden zielzellen
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
Zhang et al. Microenvironmental Self‐Optimizing HOFs Biocatalysts for Boosting Disulfidptosis‐Mediated Antitumor Immunotherapy
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
WO2006031363A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
ATE411044T1 (de) Monozyte-spezifisches teilchenförmiges verabreichungsvehikel
BR0303362A (pt) Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal
WO2003086175A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ARANA THERAPEUTICS LIMITED (AU)

Free format text: TRANSFERIDO DE: SCANCELL LIMITED

B25D Requested change of name of applicant approved

Owner name: ARANA THERAPEUTICS PTY LTD. (AU)

Free format text: NOME ALTERADO DE: ARANA THERAPEUTICS LIMITED

B25D Requested change of name of applicant approved

Owner name: CEPHALON AUSTRALIA PTY LTD. (AU)

Free format text: NOME ALTERADO DE: ARANA THERAPEUTICS PTY LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]